SCHEDULE 13G/A: TCG Crossover Reduces Cogent Biosciences Stake to 4.8%

TCG Crossover Fund I, L.P., TCG Crossover GP I, LLC, and Chen Yu have filed an amendment to their Schedule 13G, reporting a beneficial ownership of 4.8% in Cogent Biosciences, Inc.

Summary

• TCG Crossover Fund I, L.P., TCG Crossover GP I, LLC, and Chen Yu (collectively, the Reporting Persons) have filed Amendment No. 4 to their Schedule 13G.
• The Reporting Persons beneficially own an aggregate of 6,798,162 shares of Cogent Biosciences, Inc. Common Stock.
• This represents 4.8% of the Issuer's outstanding Common Stock.
• The percentage is based on 142,376,529 shares of Common Stock outstanding, as reported in Cogent Biosciences' quarterly report on Form 10-Q filed with the SEC on November 7, 2025.
• TCG Crossover GP I, LLC is the general partner of TCG Crossover Fund I, L.P., and Chen Yu is the sole managing member of TCG Crossover GP II, with both potentially sharing voting, investment, and dispositive power over these securities.

Sentiment

Score: 4

Explanation: The reduction in beneficial ownership by a significant institutional investor to below the 5% threshold is generally perceived as a slightly negative signal, indicating a decreased stake or confidence from that specific investor group.

Positives

• The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Negatives

• The beneficial ownership of the Reporting Persons has decreased to 4.8%, falling below the 5% threshold that typically triggers a new Schedule 13G filing (though this is an amendment to an existing filing). This reduction by a significant institutional investor could be perceived as a negative signal by the market.

Risks

• No specific new risks related to the company's operations or financial health are disclosed in this ownership filing. The primary risk discussed is the potential for influence over control, which the reporting persons explicitly disclaim.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May perceive the reduction in a significant institutional investor's stake as a negative signal, potentially influencing investor sentiment and share price.

Key Dates

Recommendation

The filing indicates a reduction in a significant institutional investor's stake to below 5%. While this is a factual ownership change and not a direct reflection of company performance, a decrease in institutional ownership can sometimes be interpreted as a lack of conviction or a reallocation of capital. Without additional information on the company's fundamentals or other market factors, a "hold" recommendation is prudent, suggesting investors monitor further developments rather than making immediate buy or sell decisions based solely on this ownership change.

Keywords

Cogent Biosciences, TCG Crossover, Schedule 13G, beneficial ownership, institutional investor, common stock, equity stake, SEC filing, 19240Q201